Evidence map›Paper›PMID 36483472›Full record

ArticleFrontiers in pediatrics2022

Different profiles of lipoprotein particles associate various degrees of cardiac involvement in adolescents with morbid obesity.

José M Siurana, Anna Sabaté-Rotés, Núria Amigó, Neus Martínez-Micaelo, Larry Arciniegas, Lucia Riaza, Eduard Mogas, Ferran Rosés-Noguer, Paula S Ventura, Diego Yeste

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. The Association of HDL2b with Metabolic Syndrome Among Normal HDL-C Populations in Southern China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

José M SiuranaDepartment of Pediatric Cardiology, Hospital HM Nens, HM Hospitales, Barcelona, Spain.
Anna Sabaté-RotésAutonomous University of Barcelona, Barcelona, Spain.
Núria AmigóBiosfer Teslab, Reus, Spain.
Neus Martínez-MicaeloBiosfer Teslab, Reus, Spain.
Larry ArciniegasDepartment of Pediatric Endocrinology, Vall d'Hebron University Hospital, Barcelona, Spain.
Lucia RiazaDepartment of Pediatric Radiology, Vall d'Hebron University Hospital, Barcelona, Spain.
Eduard MogasDepartment of Pediatric Endocrinology, Vall d'Hebron University Hospital, Barcelona, Spain.
Ferran Rosés-NoguerAutonomous University of Barcelona, Barcelona, Spain.
Paula S VenturaDepartment of Pediatric Endocrinology, Hospital HM Nens, HM Hospitales, Barcelona, Spain.
Diego YesteAutonomous University of Barcelona, Barcelona, Spain.
Vall d'Hebron Hospital Universitari · ESUniversitat Autònoma de Barcelona · ESInstitut d'Investigació Sanitària Pere Virgili · ESHM Hospitales · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Dyslipidemia secondary to obesity is a risk factor related to cardiovascular disease events, however a pathological conventional lipid profile (CLP) is infrequently found in obese children. The objective is to evaluate the advanced lipoprotein testing (ALT) and its relationship with cardiac changes, metabolic syndrome (MS) and inflammatory markers in a population of morbidly obese adolescents with normal CLP and without type 2 diabetes mellitus, the most common scenario in obese adolescents. Methods: Prospective case-control research of 42 morbidly obese adolescents and 25 normal-weight adolescents, whose left ventricle (LV) morphology and function had been assessed. The ALT was obtained by proton nuclear magnetic resonance spectroscopy, and the results were compared according to the degree of cardiac involvement - normal heart, mild LV changes, and severe LV changes (specifically LV remodeling and systolic dysfunction) - and related to inflammation markers [highly-sensitive C-reactive protein and glycoprotein A (GlycA)] and insulin-resistance [homeostatic model assessment for insulin-resistance (HOMA-IR)]. A second analysis was performed to compare our results with the predominant ALT when only body mass index and metabolic syndrome criteria were considered. Results: The three cardiac involvement groups showed significant increases in HOMA-IR, inflammatory markers and ALT ratio LDL-P/HDL-P (40.0 vs. 43.9 vs. 47.1, Conclusions: ALT parameters and GlycA appear to be more reliable indicators of cardiac change severity than traditional CV risk factors. Particularly, the overage of LDL-P compared to HDL-P and the increase in small LDL-P with cholesterol-depleted LDL particles appear to be the key ALT's parameters involved in LV changes. Morbidly obese adolescents show an atherosclerotic ALT and those with MS present worse ALT values.

Indexed as

adolescentsatherosclerotic phenotypecardiac changeslipoprotein subclassesmetabolic syndromemorbid obesitysmall LDL particlessystolic dysfunction

Identifiers

PMID36483472
PMCPMC9723388
OpenAlexW4309717668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.